Rosenberg, Jonathan

selected publications

Antibody-Drug Conjugates in Urothelial Carcinomas. Current oncology reports. 2020 Information Resource GET IT
Times cited: 7
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 453
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 185
MCL1 and DEDD Promote Urothelial Carcinoma Progression. Molecular cancer research : MCR. 2019 Academic Article GET IT
Times cited: 5
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2018 Academic Article GET IT
Times cited: 36
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 176
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 116
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 111
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell reports. 2018 Academic Article GET IT
Times cited: 66
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 404
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 88
Oncologist use and perception of large panel next-generation tumor sequencing. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 32
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS medicine. 2017 Academic Article GET IT
Times cited: 249
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2017 Academic Article GET IT
Times cited: 6
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 1732
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 580
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European urology. 2016 Academic Article GET IT
Times cited: 59
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer. 2016 Academic Article GET IT
Times cited: 52
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 3038
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature genetics. 2016 Academic Article GET IT
Times cited: 142
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer. 2015 Academic Article GET IT
Times cited: 26
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. The Journal of urology. 2015 Academic Article GET IT
Times cited: 50
Genomic Characterization of Upper Tract Urothelial Carcinoma. European urology. 2015 Academic Article GET IT
Times cited: 202
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 3
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC cancer. 2015 Academic Article GET IT
Times cited: 21
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. The oncologist. 2015 Academic Article GET IT
Times cited: 38
Novel molecular targets for urothelial carcinoma. Expert opinion on therapeutic targets. 2015 Information Resource GET IT
Times cited: 9
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. Hematology/oncology clinics of North America. 2014 Information Resource GET IT
Times cited: 18
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European journal of cancer. 2014 Academic Article GET IT
Times cited: 78
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 2
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 504
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. European urology. 2014 Academic Article GET IT
Times cited: 117
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer discovery. 2014 Academic Article GET IT
Times cited: 102
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer medicine. 2014 Academic Article GET IT
Times cited: 77
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 59
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Academic Article GET IT
Times cited: 2402
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investigational new drugs. 2013 Academic Article GET IT
Times cited: 308
Molecular targets on the horizon for kidney and urothelial cancer. Nature reviews. Clinical oncology. 2013 Information Resource GET IT
Times cited: 21
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 80
Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. Frontiers in pharmacology. 2013 Article GET IT
Times cited: 21
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. European urology. 2012 Academic Article GET IT
Times cited: 108
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. Urologic oncology. 2012 Information Resource GET IT
Times cited: 5
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 175
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The Lancet. Oncology. 2010 Information Resource GET IT
Times cited: 115
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Article GET IT
Times cited: 9

VIVO Weill Cornell Medical College

Jonathan Rosenberg Professor of Medicine

Publications

selected publications

Contact

full name

Phone

Publications

selected publications

Contact

full name